TNFRSF11B gene polymorphisms increased risk of peripheral arterial occlusive disease and critical limb ischemia in patients with type 2 diabetes

Acta Diabetologica

Volumn 51, Issue 6, 2014, Pages 1025-1032

  Biscetti, Federico ^a,b   Porreca, Carlo Filippo ^a,b   Bertucci, Flavio ^a,b   Straface, Giuseppe ^c   Santoliquido, Angelo ^b   Tondi, Paolo ^b   Angelini, Flavia ^a   Pitocco, Dario ^b   Santoro, Luca ^d   Gasbarrini, Antonio ^a,b   Landolfi, Raffaele ^b   Flex, Andrea ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d University Campus Biomedico   (Italy)

Author keywords

Atherosclerosis; PAOD; TNFRSF11B gene polymorphisms; Type 2 diabetes

Indexed keywords

CYSTEINE; GLYCINE; OSTEOPROTEGERIN; THREONINE; TNFRSF11B PROTEIN, HUMAN;

AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL EVALUATION; CRITICAL LIMB ISCHEMIA; DEMOGRAPHY; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENE LOCATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; TNFRSF11B GENE; ARTERIAL OCCLUSIVE DISEASES; ATHEROSCLEROSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GENETIC PREDISPOSITION; GENETICS; ISCHEMIA; LIMB; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULARIZATION;

AGED; ARTERIAL OCCLUSIVE DISEASES; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EXTREMITIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; ISCHEMIA; MALE; OSTEOPROTEGERIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84919391273     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0664-1     Document Type: Article

References (41)

1. Lim H, Kim YU, Sun H, Lee JH, Reynolds JM et al (2014) Proatherogenic conditions promote autoimmune t helper 17 cell responses in vivo. Immunity 40:153–165. doi:10.1016/j.immuni.2013.11.021
2. Marinkovic N, Pasalic D, Potocki S (2013) Polymorphisms of genes involved in polycyclic aromatic hydrocarbons’ biotransformation and atherosclerosis. Biochem Med (Zagreb) 23:255–265. doi:10.11613/BM.2013.032
3. Munger MA, Hawkins DW (2004) Atherothrombosis: epidemiology, pathophysiology, and prevention. J Am Pharm Assoc 44(Suppl 1):S5–S13
4. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR et al (1992) Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326:381–386
5. Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. JAMA 287:2570–2581. doi:10.1001/jama.287.19.2570
6. Sipilä K, Kähönen M, Salomaa V, Päivänsalo M, Karanko H et al (2012) Carotid artery intima-media thickness and elasticity in relation to glucose tolerance. Acta Diabetol 49:215–223. doi:10.1007/s00592-011-0291-z
7. Sesti G, Andreozzi F, Fiorentino TV, Mannino GC, Sciacqua A et al (2014) High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol 51:705–713. doi:10.1007/s00592-014-0576-0
8. Jung CH, Lee WY, Kim SY, Jung JH, Rhee EJ et al (2010) The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM. Acta Diabetol 47(Suppl 1):145–152. doi:10.1007/s00592-009-0154-z
9. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M et al (2004) Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109:175–180. doi:10.1161/01.CIR.0000127957.43874.BB
10. Ziegler S, Kudlacek S, Luger A, Minar E (2005) Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 182:175–180. doi:10.1016/j.atherosclerosis.2005.01.042
11. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319
12. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342. doi:10.1038/nature01658
13. Dai Y, Shen L (2007) Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women. Chin Med J (Engl) 120:2017–2021
14. Turk N, Cukovic-Cavka S, Korsic M, Turk Z, Vucelic B (2009) Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn’s disease. Eur J Gastroenterol Hepatol 21:159–166. doi:10.1097/MEG.0b013e3283200032
15. Goranova-Marinova V, Goranov S, Tzveltkova T (2007) Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations. Haematologica 92:1000–1001. doi:10.3324/haematol.10943
16. Whyte MP (2006) Paget’s disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. Ann NY Acad Sci 1068:143–164. doi:10.1196/annals.1346.016
17. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J et al (1998) Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260–1268
18. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C et al (2000) Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192:463–474. doi:10.1084/jem.192.4.463
19. Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B et al (2005) Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111:2461–2468. doi:10.1161/01.CIR.0000165119.62099.14
20. Golledge J, McCann M, Mangan S, Lam A, Karan M (2004) Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 35:1636–1641. doi:10.1161/01.STR.0000129790.00318.a3
21. Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T (2006) Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 26:857–863. doi:10.1161/ATVBAHA.108.162305
22. Straface G, Biscetti F, Pitocco D, Bertoletti G, Misuraca M et al (2011) Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. Stroke 42:3022–3028. doi:10.1161/STROKEAHA.111.619288
23. Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A (2005) Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction. Clin Sci (Lond) 109:389–395. doi:10.1042/CS20050058
24. Rutherford RB, Flanigan DP, Gupta SK, The Ad Hoc Committee on Reporting Standards SVS, ISCVS (1986) Suggested standards for reports dealing with lower extremity ischaemia. J Vasc Surg 4:80–94
25. Dormandy JA, Rutherford RB (2000) Management of peripheral arterial disease (PAD). TASC working group. TransAtlantic inter-society consensus (TASC). J Vasc Surg 31:S1–S296
26. Biscetti F, Straface G, Giovannini S, Santoliquido A, Angelini F et al (2013) Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients. Hum Genet 132:49–55. doi:10.1007/s00439-012-1224-9
27. Attia I, Thakkinstian A, D’Este C (2003) Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 56:297–303
28. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G (2006) The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 4:801–811. doi:10.1586/14779072.4.6.801
29. Van Campenhout A, Golledge J (2009) Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 204:321–329. doi:10.1016/j.atherosclerosis.2008.09.033
30. Doherty TM, Asotra K, Fitzpatrick LA, Qiao JH, Wilkin DJ (2003) Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci USA 10:11201–11206. doi:10.1073/pnas.1932554100
31. Candido B, Toffoli F, Corallini S, Bernardi D, Zella R (2010) Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res 47:252–261. doi:10.1016/j.mce.2010.08.019
32. Caidahl K, Ueland T, Aukrust P (2010) Osteoprotegerin: a biomarker with many faces. Arterioscler Thromb Vasc Biol 30:1684–1686. doi:10.1161/ATVBAHA.110.208843
33. Sage AP, Tintut Y, Demer LL (2010) Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 7:528–536. doi:10.1038/nrcardio.2010.115
34. Shao JS, Cheng SL, Sadhu J, Towler DA (2010) Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension 55:579–592. doi:10.1161/HYPERTENSIONAHA.109.134205
35. Sangiorgi G, Rumberger JA, Severson A, Edwards WD, Gregoire J (1998) Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol 31:126–133. doi:10.1016/S0735-1097(97)00443-9
36. Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y (2004) Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation 110:3424–3429. doi:10.1161/01.CIR.0000148131.41425.E9
37. Vliegenthart R, Oudkerk M, Song B, van der Kuip DA, Hofman A, Witteman JC (2002) Coronary calcification detected by electron-beam computed tomography and myocardial infarction. The rotterdam coronary calcification study. Eur Heart J 23:1596–1603
38. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G (2008) Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 358:1336–1345. doi:10.1056/NEJMoa072100
39. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176. doi:10.1016/S0092-8674(00)81569-X
40. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM (2006) Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE−/− mice. Arterioscler Thromb Vasc Biol 26:2117–2124. doi:10.1161/01.ATV.0000236428.91125.e6
41. Jono S, Ikari Y, Shioi A, Mori K, Miki T (2002) Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106:1192–1194. doi:10.1161/01.CIR.0000031524.49139.29